<DOC>
	<DOC>NCT00596479</DOC>
	<brief_summary>The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.</brief_summary>
	<brief_title>Filgrastim for the Promotion of Collateral Growth in Patients With CAD</brief_title>
	<detailed_description>The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age &gt; 18 years old 1 to 3vessel coronary artery disease (CAD) Stable angina pectoris At least 1 stenotic lesion suitable for PCI No Qwave myocardial infarction in the area undergoing CFI measurement Written informed consent to participate in the study Patients admitted as emergencies Acute myocardial infarction Unstable CAD CAD treated best by CABG Patients with overt neoplastic disease Patients with diabetic retinopathy Liver or kidney disease Premenopausal women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CAD</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Collaterals</keyword>
	<keyword>CFI</keyword>
	<keyword>perfusion</keyword>
</DOC>